Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 3 months ago
1 mg
1 mg vial
৳76,087.00 per pack

Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.

All price changes →
From ৳76,087.00 1 mg vial
Available as: 1 mg · 1 mg vial

Indications & Uses

Coagulation Factor VIIa [Eptacog Alfa] is used to treat bleeding episodes in people with haemophilia. It is also used for bleeding episodes due to surgery or invasive procedures in patients with factor VII deficiency, and for the same kind of bleeding in patients with Glanzmann's thrombasthenia.

Pharmacology

Eptacog alfa is a recombinant form of activated factor VII, made by recombinant DNA technology, so it is a biosynthetic preparation. It is a vitamin K-dependent glycoprotein. The medicine helps stop bleeding by activating the extrinsic pathway of the coagulation cascade. It replaces deficient activated coagulation factor VII, which forms a complex with tissue factor and may activate coagulation factor X and factor IX. Factor VIIa is given in this recombinant form, eptacog alfa (activated).

Dosage Reference

Reference Information Only

Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.

Adults:

For adults with haemophilia who have a bleeding episode, Coagulation Factor VIIa (as activated eptacog alfa) starts at 90 mcg/kg, given as an IV bolus over 2 to 5 min. More doses can be given as needed to reach or maintain haemostasis, at first every 2 to 3 hours. The dose or the gap between doses may be adjusted according to response, and in serious bleeding episodes therapy may continue for up to 3 weeks or more. For bleeding episodes due to surgery or invasive procedures in adults with factor VII deficiency, the dose of activated eptacog alfa is 15 to 30 mcg/kg every 4 to 6 hours by IV bolus over 2 to 5 min, until haemostasis is achieved. For bleeding episodes due to surgery or invasive procedures in Glanzmann's thrombasthenia, adults receive 90 mcg/kg every 2 hours by IV bolus over 2 to 5 min, and at least 3 doses should be given.

Side Effects

Coagulation Factor VIIa (Eptacog Alfa) can cause nausea, vomiting, skin reactions, fever, headache and changes in BP. Anaphylaxis is rare.

Cautions & Contraindications

Warnings & Precautions

Take care with Coagulation Factor VIIa (Eptacog Alfa) in people with advanced atherosclerotic disease, crush injury, septicemia or disseminated intravascular coagulation. The same care applies to patients with a history of CHD or liver disease, those undergoing major surgery, and those at risk of thromboembolic phenomena or disseminated intravascular coagulation. There is a remote possibility of hypersensitivity to mouse IgG, bovine IgG and other residual culture proteins. In patients with factor VII deficiency, monitor prothrombin time and factor VII coagulant activity. Use caution in pregnancy and lactation, and in neonates.

Contraindications

Don't give Coagulation Factor VIIa (Eptacog Alfa) to anyone who is hypersensitive to recombinant coagulation factor VIIa, or to mouse, hamster or bovine protein. It is also not for people with rare hereditary problems of fructose intolerance, glucose malabsorption or sucrose-isomaltase insufficiency.

Pregnancy & Breastfeeding

Try to avoid Coagulation Factor VIIa (eptacog alfa) during pregnancy. Animal studies have shown harmful effects on the foetus (teratogenic, embryocidal or other), and there are either no controlled studies in women or no studies in women and animals at all. The medicine should be given only if the possible benefit justifies the possible risk to the foetus.

Nobody knows yet whether eptacog alfa passes into human breast milk. Its excretion in milk hasn't been studied in animals either.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Common questions about NovoSeven 1 mg

What is NovoSeven 1 mg IV Injection?

NovoSeven 1 mg IV Injection is a medicine that contains Coagulation Factor VIIa [Eptacog Alfa]. It is made by Novo Nordisk Pharma (Pvt.) Ltd. It belongs to the Anti-fibrinolytic drugs group of medicines.

What is NovoSeven used for?

Coagulation Factor VIIa [Eptacog Alfa] is used to treat bleeding episodes in people with haemophilia. It is also used for bleeding episodes due to surgery or invasive procedures in patients with factor VII deficiency, and for the same kind of bleeding in patients with Glanzmann's thrombasthenia.

What are the side effects of NovoSeven?

Coagulation Factor VIIa (Eptacog Alfa) can cause nausea, vomiting, skin reactions, fever, headache and changes in BP. Anaphylaxis is rare.

Can I take NovoSeven during pregnancy or while breastfeeding?

Try to avoid Coagulation Factor VIIa (eptacog alfa) during pregnancy. Animal studies have shown harmful effects on the foetus (teratogenic, embryocidal or other), and there are either no controlled studies in women or no studies in women and animals at all. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Do I need a prescription for NovoSeven?

NovoSeven is a prescription (Rx) medicine. Take it as your doctor advises.

Last updated: 18 Aug 2026